Oncotelic Therapeutics, Inc.
Other OTCTotal Valuation
Oncotelic Therapeutics, Inc. carries a market capitalization of 9.15M, placing it among publicly traded companies globally. Its enterprise value stands at 19.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.15M |
| Enterprise Value | 19.50M |
Share Statistics
Oncotelic Therapeutics, Inc. currently has 444.20M shares outstanding.
| Shares Outstanding | 444.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Oncotelic Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 0.08.
| PE Ratio | 0.08 |
| PS Ratio | N/A |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -13.67 |
| P/OCF Ratio | -13.46 |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 0.79 |
Financial Position
Oncotelic Therapeutics, Inc. maintains a current ratio of 0.26, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 182.51, indicating elevated leverage, while an interest coverage ratio of -6.33 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.26 |
| Quick Ratio | 0.03 |
| Debt / Equity | 182.51 |
| Debt / EBITDA | N/A |
| Interest Coverage | -6.33 |
Financial Efficiency
Oncotelic Therapeutics, Inc. posts a return on equity of 5,953.69 and a return on invested capital of -46.54.
| Return on Equity (ROE) | 5,953.69 |
| Return on Assets (ROA) | 1,852.32 |
| Return on Invested Capital (ROIC) | -46.54 |
| Return on Capital Employed (ROCE) | 2,368.79 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oncotelic Therapeutics, Inc.'s stock has declined approximately -80% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -80% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -4.87M, while operating income came in at -4.87M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -4.87M |
| Pretax Income | 358.49M |
| Net Income | 247.11M |
| EBITDA | -4.87M |
| EBIT | -4.87M |
| Earnings Per Share (EPS) | 0.55 |
Cash Flow
Oncotelic Therapeutics, Inc. produced -1.43M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.43M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.43M |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.22 |
| FCF Yield | -7.31 |
Stock Splits
Oncotelic Therapeutics, Inc.'s most recent stock split took place on December 28, 2012 with a 12:1 split ratio.
| Last Split Date | 12/28/2012 |
| Split Ratio | 12:1 |
Scores
Oncotelic Therapeutics, Inc. posts an Altman Z-Score of -0.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.67 |